Deal Snapshot
Tolero and Boston Biomedical Merge to Create Sumitomo Dainippon Pharma Oncology
Monday 06 July 2020

Sumitomo Dainippon Pharma, Inc. subsidiaries, Tolero Pharmaceuticals, Inc. and Boston Biomedical, Inc., two US clinical-stage companies developing novel cancer therapeutics, have merged to form Sumitomo Dainippon Pharma Oncology to advance therapies for patients with cancer, the company said.

Terms of the transaction were not disclosed. This US entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology.

Date Published: 06/07/2020